Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD.

摘要

Reactivation of resolved hepatitis B virus (HBV) infection is a frequent complication in allogeneic hematopoietic SCT (HSCT) recipients. In a retrospective assessment among patients with resolved HBV infection (hepatitis B core Ab-positive, hepatitis B surface Ag-negative), the cumulative risk of HBV reactivation rose from 9 to 13% per year of survival after HSCT, resulting in a cumulative probability of 42.9% at 4 years after HSCT. The risk for liver cirrhosis increases significantly with the level of the circulating virus. Patients with nucleos(t)ide analogue therapy have a significantly lower incidence of hepatocellular cancer compared with untreated patients (2.8 vs 6.4%, P 0.003). Therefore, patients may benefit from antiviral therapy.